Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05508074
Other study ID # P288ALS
Secondary ID 2021-003875-32
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date December 2, 2022
Est. completion date January 2025

Study information

Verified date March 2024
Source InFlectis BioScience
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective, international, randomised, double-blind, placebo controlled, multicentre, parallel group study. Patients will be randomised in a 2:1 allocation ratio to receive either IFB-088 + riluzole 100 mg or placebo + riluzole 100 mg. This clinical trial is an exploratory study, designed to show a signal of efficacy of IFB-088 through ALSFRS-R, MITOS and King's College. Respiratory function will be followed through SVC. Biomarkers and quality of life will also be evaluated throughout the study. Patients will be treated over a 6-month period. After a screening/consent visit, patients will undergo clinic visits at randomisation (V0), at 2 weeks (V1), and at months 1 (V2), 3 (V3) and 6 (V4). One week after V0, the patient will undergo urine analysis (dipstick)and blood sampling for measurement of creatinine , as well as blood sampling for measurement of creatinine and calculation of eGFR at months 2, 4 and 5. At the V2 visit, in addition to other assessments, patients will undergo blood sampling for PK measurements and urine sampling for crystalluria examination. Blood and urine chemistry, as well as physical examination and vital signs assessment to assess safety will be performed at each visit for safety purpose and crystalluria examination will be repeated at the follow-up visit, performed one month ± one week after V4.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 51
Est. completion date January 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Diagnosis of probable or definite ALS according to the revised El Escorial criteria [29], with bulbar onset of disease, familial or sporadic form, 2. Onset of symptoms = 18 months prior to screening, as reported by the patient, 3. Adult males or females, aged at least 18 years old, 4. SVC > 60% of predicted value for age and sex, 5. ALSFRS-R score = 36, 6. Treatment with riluzole 100 mg/day, at stable dose since at least one month and well tolerated, 7. Male or female patient of childbearing potential10 who agrees to use highly effective mechanical contraception methods (sexual abstinence, intrauterine device, bilateral tubal occlusion, vasectomised partner) throughout the study, and for 3 months after the end of the treatment, 8. Patient who read, understood and signed the ICF, 9. Patient who is willing to adhere to the study visit schedule and is capable to understand and comply with protocol requirements. Exclusion Criteria: 1. Known other significant neurological disease(s), 2. Serious illness(es) or medical condition(s) (e.g. unstable cardiac disease, cancer, hematologic disease, hepatitis or liver failure, renal failure) that is not stabilised or that could require hospitalisation and may jeopardise the participation in the study, 3. Abnormal renal function at screening defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2, 4. Abnormal liver function at screening defined as total bilirubin levels >1.5 ULN, and/or AST and/or ALT >3 ULN, 5. Neutropenia (ANC <1.5 x 109/L) at screening, 6. Other causes of neuromuscular weakness, 7. Non progressive or very rapidly progressing ALS (ALSFRS-R decline from disease onset to randomisation = 0.1 / month or = 1.2 / month)11, 8. Non-invasive ventilation, 9. Tracheotomy, 10. Weight loss = 10% compared to weight at symptoms onset as declared by the patient or BMI <18 kg/m2 at screening, 11. Dementia or other severe active psychiatric illness, including suicidal ideation assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS), 12. Patient with a significant pulmonary disorder not attributed to ALS or who require treatments that might complicate the evaluation of the effect of ALS on respiratory function, 13. Patient treated by edaravone for ALS, 14. Patient using unauthorised concomitant treatments, namely moderate or strong inhibitors or inducers of CYP1A2, strong inhibitors or inducers of CYP2D6 or 2C19 and strong inhibitors of OCT2, as listed in Section 6.2. Combined oral contraceptives containing ethinylestradiol are forbidden concomitant medications, 15. Smoker of > 10 cigarettes per day (e-cigarettes and nicotine patches are permitted), 16. Known hypersensitivity to any of the ingredients or excipients of the IMPs, 17. Pregnant, lactating women, 18. Patient who participated in another trial of investigational drug(s) within 30 days prior to randomisation, or 5 half-lives of the previous investigational product, whichever is longer, 19. Patient who has forfeited their freedom by administrative or legal award, or who is under guardianship or under limited judicial protection.

Study Design


Intervention

Drug:
IFB-088 50mg/day
Tested product
Placebo
Placebo
Riluzole 100mg/day
Standard of care treatment, co-administered with tested product (IFB-088 50mg/day) or placebo

Locations

Country Name City State
France Hôpital Neurologique Pierre Wertheimer Bron
France APHM Hôpital La Timone Adultes SCE Maladies Neuromusculaires / SLA Marseille Cedex 05
France Hôpital Central NANCY Cedex
France CHU de Nantes - Hôpital Laennec Nantes
France CHU de Nice Pasteur 2-zone C NICE Cedex 1
France CHU de Toulouse - Hôpital Pierre-Paul Riquet Toulouse Cedex 9
France CHU Bretonneau Tours Cedex 1
Italy Ospedale Civile Sant'Agostino Estense Baggiovara
Italy Centro Clinico NeMO per le Malattie Neuromuscolari Gussago
Italy IRCSS Istituto Neurologico Carlo Besta Milano
Italy Sant'Andrea Hospital Unit of Neuromuscular Disorders Roma

Sponsors (1)

Lead Sponsor Collaborator
InFlectis BioScience

Countries where clinical trial is conducted

France,  Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety assessment of IFB-088 50 mg/day in patients with bulbar-onset ALS. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Incidence, grade and relationship to IFB-088 for treatment emergent AEs, SAEs, and AESIs,
AEs leading to dose interruption or premature discontinuation.
from beginning of IMP intake up to 30 days after stopping the intake
Secondary Efficacy with scale : ALSFRS-R (ALS Functional Rating Scale Revised) ALSFRS-R (ALS Functional Rating Scale Revised) 12 items, clinician rated including 5 choices from normal to disabled. Efficacy scale from baseline to 3 months and 6 months.
Secondary Efficacy with scale : ALS_MITOS (ALS Milano-Torino Staging) ALS_MITOS (ALS Milano-Torino Staging), 4 domains, clinician rated, Staging determined by the sum of functional score of 1 for each domain. Efficacy scale from baseline to 3 months and 6 months.
Secondary Efficacy with scale : King's college Scale (ALS staging form) King's college Scale (King's ALS staging form), clinician rated, 8 items. Efficacy scale from baseline to 3 months and 6 months.
Secondary Efficacy based on assessment of respiratory function (slow vital capacity [SVC]) Assessment of respiratory function (slow vital capacity [SVC]). Respiratory function at screening, 3 and 6 months.
Secondary Efficacy based on assessment of respiratory function (Arterial Blood Gases [ABG]) Assessment of respiratory function (Arterial Blood Gases [ABG]). Respiratory function at screening, 3 and 6 months.
Secondary Efficacy based on assessment of nutritional status (exploratory) change of nutritional status (fat mass) evaluated by bioelectrical impedance At baseline and 6 months
Secondary Efficacy based on assessment of body composition (exploratory) change of body composition (% of water, muscle, bone in the body) evaluated by bioelectrical impedance At baseline and 6 months
Secondary Pharmacokinetic parameters (Plasma concentration) Plasma concentration of IFB-088 and IFB-139. PK parameters will be analysed after 4 weeks of treatment.
Secondary Pharmacokinetic parameters (Area Under Curve [AUC]) AUC of IFB-088 and IFB-139. PK parameters will be analysed after 4 weeks of treatment.
Secondary Pharmacokinetic parameters (Cmax) Maximum observed plasma concentration (Cmax) PK parameters will be analysed after 4 weeks of treatment.
Secondary Pharmacokinetic parameters (Tmax) Time at which maximum plasma concentration (Cmax) is measured PK parameters will be analysed after 4 weeks of treatment.
Secondary Pharmacokinetic parameters (t1/2) Terminal or apparent terminal half-life (t1/2). PK parameters will be analysed after 4 weeks of treatment.
Secondary Pharmacokinetic parameters (clearance) Apparent systemic clearance. PK parameters will be analysed after 4 weeks of treatment.
Secondary Pharmacokinetic parameters (Vd) Apparent volume of distribution (Vd). PK parameters will be analysed after 4 weeks of treatment.
Secondary Biomarkers (TDP-43) Change in TDP-43 plasmatic concentration from baseline to 6 months, compared to placebo (concentration in pg/mL, technology Simoa®). At baseline and 6 months.
Secondary Biomarkers (neurofilament light chain) Change in neurofilament (NfL) light chain plasmatic concentration from baseline to 6 months, compared to placebo (concentration in pg/mL, technology Simoa®). At baseline and 6 months.
Secondary Biomarkers (Inflammation biomarkers) Inflammation biomarkers (interleukin [IL]-6, tumour necrosis factor-a [TNFa], interferon ? [IFN?], IL-1ß, IL-8, IL-10, monocyte chemoattractant protein-1 [MCP-1], nerve growth factor [NGF], brain-derived neurotrophic factor [BDNF], vascular endothelial growth factor [VEGF]): at baseline, 3 and 6 months (concentration of each biomarker in ng/mL, technology Luminex®)). At baseline, 3 months, and 6 months.
Secondary Biomarkers (3-Nitrotyrosine) 3-Nitrotyrosine (Oxidative stress biomarker): at baseline, 3 and 6 months (concentration in ng/mL, ELISA method). At baseline, 3 months, and 6 months.
Secondary Quality of Life with ALSAQ-40 (ALS Assessment Questionnaire) Change in ALS assessment questionnaire (ALSAQ-40). ALSAQ-40 (ALS Assessment Questionnaire) Quality of Life questionnaire 40 items, patient rated including 5 choices from never to always. QoL will be assessed from baseline to 6 months
See also
  Status Clinical Trial Phase
Terminated NCT04428775 - A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease Phase 2
Recruiting NCT04998305 - TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps Phase 1/Phase 2
Recruiting NCT05951556 - Telehealth Implementation of Brain-Computer Interface N/A
Terminated NCT04579666 - MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Recruiting NCT04082832 - CuATSM Compared With Placebo for Treatment of ALS/MND Phase 2/Phase 3
Completed NCT01925196 - Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
Completed NCT02496767 - Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year Phase 3
Recruiting NCT04816227 - Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
Active, not recruiting NCT04494256 - A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation Phase 1/Phase 2
Completed NCT03706391 - Study of ALS Reversals 4: LifeTime Exposures
Recruiting NCT04882904 - Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part. N/A
Completed NCT04557410 - Open Label Study: Treatment of ALS Fatigue With PolyMVA Phase 1
Active, not recruiting NCT04948645 - A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis Phase 1
Not yet recruiting NCT04089696 - Validation of the "ExSpiron©" in Patients With ALS N/A
Not yet recruiting NCT04220190 - RAPA-501 Therapy for ALS Phase 2/Phase 3
Not yet recruiting NCT06450691 - Modeling Amyotrophic Lateral Sclerosis With Fibroblasts N/A
Not yet recruiting NCT05860244 - Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients Phase 2
Recruiting NCT02917681 - Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis Phase 1/Phase 2
Active, not recruiting NCT03067857 - Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease Phase 1/Phase 2
Recruiting NCT02874209 - Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis N/A